RankAlpha logo
Back to Rankings

RZLT

RezoluteF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The constructive part of the March 2026 FDA interaction is that the agency did not shut down sunRIZE after the miss and instead asked for a fuller data package, while the company still has a second Phase 3 program, upLIFT, due in H2 2026. If either the congenital HI review or tumor HI readout restores confidence in ersodetug's efficacy path, the stock has room toward the roughly $4.75 sell-side median target.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Dilutive financing risk can return if the congenital HI path stretches or tumor HI data slip
Momentum
32
Value
41
Sentiment
34
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.50 · Bull $4.80 · Bear $2.10
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-18 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $4.75
Why
Momentum32 · Δ7d +6.4
Value41 · Δ7d +0.1
Sentiment34 · Δ7d -7.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
32
34% active weight
Current posture
7d trendImproving
Δ7d
+6.4
Δ21d
+9.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
34
33% active weight
Current posture
7d trendSoftening
Δ7d
-7.4
Δ21d
-5.4
Why this grade

Composite grade F. Momentum 31.6 / Value 41.1 / Sentiment 33.6

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$347.62M
Beta
0.47
Shares Out
92.73M
P/E (TTM) · Derived
-3.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.49
Rev YoY
-
EPS YoY
+20.4%
Gross Margin
-
Op Margin
-
Net Debt
-$167.86M
Current Ratio
15.15
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology